Home LiteratureArticle Details
PMID: 9002493 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group.

JAMA ·Vol. 277 ·No. 4 ·1997-00-00 ·Pages 307-11

Bates DW, Spell N, Cullen DJ, Burdick E, Laird N, Petersen LA, Small SD, Sweitzer BJ, Leape LL

Abstract

To assess the additional resource utilization associated with an adverse drug event (ADE). Nested case-control study within a prospective cohort study. The cohort included 4108 admissions to a stratified random sample of 11 medical and surgical units in 2 tertiary-care hospitals over a 6-month period. Cases were patients with an ADE, and the control for each case was the patient on the same unit as the case with the most similar pre-event length of stay. Postevent length of stay and total costs. Incidents were detected by self-report stimulated by nurses and pharmacists and by daily chart review, and were classified as to whether they represented ADEs. Information on length of stay and charges was obtained from billing data, and costs were estimated by multiplying components of charges times hospital-specific ratios of costs to charges. During the study period, there were 247 ADEs among 207 admissions. After outliers and multiple episodes were excluded, there were 190 ADEs, of which 60 were preventable. In paired regression analyses adjusting for multiple factors, including severity, comorbidity, and case mix, the additional length of stay associated with an ADE was 2.2 days (P=.04), and the increase in cost associated with an ADE was $3244 (P=.04). For preventable ADEs, the increases were 4.6 days in length of stay (P=.03) and $5857 in total cost (P=.07). After adjusting for our sampling strategy, the estimated postevent costs attributable to an ADE were $2595 for all ADEs and $4685 for preventable ADEs. Based on these costs and data about the incidence of ADEs, we estimate that the annual costs attributable to all ADEs and preventable ADEs for a 700-bed teaching hospital are $5.6 million and $2.8 million, respectively. The substantial costs of ADEs to hospitals justify investment in efforts to prevent these events. Moreover, these estimates are conservative because they do not include the costs of injuries to patients or malpractice costs.

MeSH Terms
Boston Case-Control Studies Costs and Cost Analysis Drug Therapy/economics Drug-Related Side Effects and Adverse Reactions Female Hospital Bed Capacity, 500 and over Hospital Charges/statistics & numerical data Hospital Costs/statistics & numerical data Hospitals, Urban/economics,statistics & numerical data Humans Length of Stay/economics,statistics & numerical data Linear Models Male Middle Aged Multivariate Analysis Pharmaceutical Preparations/economics Prospective Studies
Chemicals
Pharmaceutical Preparations
Authors & Affiliations
9 authors, click to expand affiliations / ORCID
Bates D W
Division of General Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Spell N
Cullen D J
Burdick E
Laird N
Petersen L A
Small S D
Sweitzer B J
Leape L L
Article Info
Journal
JAMA
Abbr.
JAMA
ISSN
0098-7484
Published
1997-00-00
Pages
307-11
Language
English
Region
United States
NLM ID
7501160
Subset
IM
Grants
AHRQ HHS · R01-HS07107-01 · United States
Corrections
CommentIn
CommentIn
CommentIn
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]